Journal article
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial
- Abstract:
-
Background: A blood-stage Plasmodium falciparum malaria vaccine would provide a second line of defence to complement partially effective or waning immunity conferred by the approved pre-erythrocytic vaccines. RH5.1 is a soluble protein vaccine candidate for blood-stage P falciparum, formulated with Matrix-M adjuvant to assess safety and immunogenicity in a malaria-endemic adult and paediatric population for the first time.
Methods: We did a n...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.1MB, Terms of use)
-
- Publisher copy:
- 10.1016/s1473-3099(24)00312-8
Authors
- Publisher:
- Elsevier
- Journal:
- Lancet Infectious Diseases More from this journal
- Volume:
- 24
- Issue:
- 10
- Pages:
- 1105-1117
- Place of publication:
- United States
- Publication date:
- 2024-06-13
- Acceptance date:
- 2024-05-10
- DOI:
- EISSN:
-
1474-4457
- ISSN:
-
1473-3099
- Pmid:
-
38880111
- Language:
-
English
- Keywords:
- Pubs id:
-
2009099
- Local pid:
-
pubs:2009099
- Deposit date:
-
2024-07-22
- ARK identifier:
Terms of use
- Copyright holder:
- Silk et al.
- Copyright date:
- 2024
- Rights statement:
- © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
- Notes:
- For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript (AAM) version arising from this submission.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record